Free Trial

Novozymes A/S (OTCMKTS:NVZMY) Sees Large Volume Increase - What's Next?

Novozymes A/S logo with Basic Materials background

Novozymes A/S (OTCMKTS:NVZMY - Get Free Report) shares saw strong trading volume on Monday . 87,366 shares changed hands during mid-day trading, an increase of 139% from the previous session's volume of 36,516 shares.The stock last traded at $70.01 and had previously closed at $69.85.

Novozymes A/S Price Performance

The company has a quick ratio of 1.04, a current ratio of 1.66 and a debt-to-equity ratio of 0.11. The stock has a market capitalization of $32.71 billion, a price-to-earnings ratio of 44.21, a price-to-earnings-growth ratio of 1.32 and a beta of 0.91. The firm has a 50-day moving average of $71.22 and a two-hundred day moving average of $63.29.

About Novozymes A/S

(Get Free Report)

Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Novozymes A/S Right Now?

Before you consider Novozymes A/S, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novozymes A/S wasn't on the list.

While Novozymes A/S currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Why Drone Stocks Are Skyrocketing Right Now!
Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters
This Strategy Beat the S&P—And Most Investors Ignore It

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines